RHT is looking like its going to make it , big year ahead if they can execute this first part?
The Company also has a well-advanced acquisition pipeline to expand its capabilities and operations in the prolific and higher margin clinical trial ecosystem. The first transaction is expected to be funded from existing available cash and debt and will strongly contribute to earnings and provide a platform for future growth and further expansion of the Company’s capabilities.
As set out in the November 2023 AGM presentation the Company continues to progress its strategy of leveraging its large global footprint of imaging and clinical trial customers to gain a greater share of spending within the clinical trial ecosystem.
To this end the Company continues to invest in bringing new products to market, such as non-invasive liver fibrosis assessment (where we continue to progress our extended proof of concept trial), along with a pipeline of product extensions and improvements including shorter MRI acquisition times, Cardiac T2* on 3T scanners, and others.
Progress has also been made on a Product Partnership & Reseller Agreement and a Technology Agreement with a software-as-a-medical device (SaMD) vendor to facilitate a seamless PACs integration solution that includes native anonymisation and encryption. The benefit of these agreements would be more streamlined workflows and reduced administrative burden for customers, and the ability to sell products to a wider audience, and to sell additional products to existing customers.
RHT Price at posting:
5.9¢ Sentiment: None Disclosure: Held
